Vpriv®

Understanding Vpriv®
Vpriv® (velaglucerase alfa) is a prescription medicine used as long‑term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease. Vpriv® is intended to replace the deficient enzyme glucocerebrosidase to reduce the accumulation of glucocerebroside in affected cells and tissues.

How Vpriv® Works:

• Enzyme replacement: Vpriv® is a hydrolytic lysosomal glucocerebroside‑specific enzyme (velaglucerase alfa) that replaces deficient glucocerebrosidase activity, enabling macrophages to degrade accumulated glucocerebroside.
• Cellular uptake and lysosomal activity:After reconstitution and intravenous administration, velaglucerase alfa is taken up by target cells and delivered to lysosomes where it exerts its enzymatic activity to reduce substrate accumulation.

FDA Approval:

2010 – Vpriv® (velaglucerase alfa) received initial U.S. approval in 2010 for long‑term enzyme replacement therapy in patients with type 1 Gaucher disease. The product label lists Initial U.S. Approval: 2010.

For more information, please visit the Vpriv® patient website. Speak with your healthcare provider to determine if Vpriv® is the right treatment option for you.